These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 19538067)
1. Concerns about "Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study". Lustberg ME; Schlesinger LS; Mangino JE Clin Infect Dis; 2009 Jul; 49(2):313; author reply 314-5. PubMed ID: 19538067 [No Abstract] [Full Text] [Related]
2. Noninferiority of linezolid for skin and bloodstream infections. Drekonja DM Clin Infect Dis; 2009 Jul; 49(2):312; author reply 314-5. PubMed ID: 19538066 [No Abstract] [Full Text] [Related]
3. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714 [TBL] [Abstract][Full Text] [Related]
4. Cochrane in context: Linezolid versus vancomycin for skin and soft tissue infections. Steiner M Evid Based Child Health; 2014 Mar; 9(1):167-8. PubMed ID: 25404580 [No Abstract] [Full Text] [Related]
5. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794 [TBL] [Abstract][Full Text] [Related]
6. The impact of linezolid and vancomycin treatment on local signs and symptoms of inflammation among pediatric patients with complicated skin and skin structure infections. Deville JG; Equils O; Huang DB; Ang JY Clin Pediatr (Phila); 2011 Nov; 50(11):1064-7. PubMed ID: 21098522 [No Abstract] [Full Text] [Related]
7. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250 [TBL] [Abstract][Full Text] [Related]
8. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Wesson KM; Lerner DS; Silverberg NB; Weinberg JM Dis Mon; 2004 Jul; 50(7):395-406. PubMed ID: 15280870 [No Abstract] [Full Text] [Related]
9. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Wesson KM; Lerner DS; Silverberg NB; Weinberg JM Clin Dermatol; 2003; 21(1):64-70. PubMed ID: 12609590 [No Abstract] [Full Text] [Related]
11. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472 [TBL] [Abstract][Full Text] [Related]
12. [Contribution of linezolid to the treatment of complicated infections of the skin and soft tissues]. Gauzit R Presse Med; 2003 Apr; 32(13 Pt 2):S17-20. PubMed ID: 12754445 [TBL] [Abstract][Full Text] [Related]
13. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Stein GE; Wells EM Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750 [TBL] [Abstract][Full Text] [Related]
15. Linezolid resistance in three isolates of coagulase-negative staphylococci. Cieloszyk K; Amodio-Groton M; Saeed M; Coyle CM Ann Pharmacother; 2007 Mar; 41(3):526-7. PubMed ID: 17341527 [No Abstract] [Full Text] [Related]